Skip to content
value.today

Adaptive Phage Therapeutics, Inc.

🇺🇸 Gaithersburg, Maryland, USABiotechnologyFounded 2017
Total raised
$35 M
2 rounds on record
Latest round
$12 M
May 2023
First round on record
May 2021
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Adaptive Phage Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2023$12 MNo. 2$10 to $50 million

Adaptive Phage Therapeutics, Inc.: Raise no. 2, May 2023

Investors in this round

4 investors had bought by the notice of Jun 9, 2023: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$12 M of $30 M offered; $18 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Gregory L. Merril · Executive Officer, Director, Promoter
  • Michael L. Orndorff · Executive Officer
  • Subhendu L. Basu · Executive Officer
  • Carl R. Merril · Director
  • Evan L. Loh · Director
  • Ian L. Hardy · Director
  • Jana L. Jensen · Director
  • Jesse L. Goodman · Director
  • Jonathan L. Leff · Director
  • Martin L. Heidecker · Director
  • Raymond L. Martz · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Gregory L. Merril, Chief Executive Officer. Newest notice filed Jun 9, 2023. Read the notice at the SEC.

equitySEC
May 2021$23 MNo. 1$10 to $50 million

Adaptive Phage Therapeutics, Inc.: Raise no. 1, May 2021

Investors in this round

59 investors had bought by the notice of May 20, 2021: 59 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$23 M of $53 M offered; $30 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Carl R. Merril · Executive Officer, Director
  • Gregory L. Merril · Executive Officer, Director, Promoter
  • Evan L. Loh · Director
  • Jana L. Jensen · Director
  • Jonathan L. Leff · Director
  • Raymond L. Martz · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The amount sold includes the convertible debt issued in exchange for equity.”

Signed by Gregory L. Merril, Chief Executive Officer. Newest notice filed May 20, 2021. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Adaptive Phage Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2023).

    SEC Form D · Jun 2023

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jun 2023

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Adaptive Phage Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Adaptive Phage Therapeutics, Inc.
NameRoleNamed in
Gregory L. MerrilExecutive officerJun 2023
Michael L. OrndorffExecutive officerJun 2023
Subhendu L. BasuExecutive officerJun 2023
Carl R. MerrilExecutive officerMay 2021
Carl R. MerrilDirectorJun 2023
Evan L. LohDirectorJun 2023
Gregory L. MerrilDirectorJun 2023
Ian L. HardyDirectorJun 2023
Jana L. JensenDirectorJun 2023
Jesse L. GoodmanDirectorJun 2023
Jonathan L. LeffDirectorJun 2023
Martin L. HeideckerDirectorJun 2023
Raymond L. MartzDirectorJun 2023
Gregory L. MerrilPromoterJun 2023